-- Cash Balance of $52.9 million to fund operations well into 2024 -- -- Initiation of a drug development program in schizophrenia -- -- Initiation of a drug development program in multiple sclerosis -- -- Launched ketamine clinics in the U.K. and U.S. and expanded treatment options --